Biologics Safety Testing Market Size by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029
Report Code: BT 3334 May, 2024, by marketsandmarkets.com
The size of global biologics safety testing market in terms of revenue was estimated to be worth $4.2 billion in 2024 and is poised to reach $7.2 billion by 2029, growing at a CAGR of 11.1% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
Growth of the market can be attributed to factors such as the rising need for novel biotherapeutics and increasing focus on advancement of biopharmaceutical industry. However, ethical concern about animal testing may hamper the growth of the market.
Biologics Safety Testing Market- Global Forecast to 2029
To know about the assumptions considered for the study, Request for Free Sample Report
Attractive Opportunities in the Biologics Safety Testing Market
Global Biologics Safety Testing Market Dynamics
DRIVER: Increasing development of mAbs and biosimilars
The growing development of monoclonal antibodies (mAbs) and biosimilars has significantly impacted the biologics safety testing market. With the rise in mAb therapeutics, especially for oncology and autoimmune diseases, there is an increased demand for stringent safety testing to ensure product quality and patient safety. The rising development of mAbs and biosimilars is propelling the growth of market. For instance, in 2024, FDA approved various biosimilars such as Tyenne (tocilizumab-aazg), Jubbonti and Wyost (denosumab-bbdz), and Simlandi (adalimumab-ryvk). Furthermore, the rising number of approvals for antibody therapeutics is propelling the growth of market. For instance, according to the Antibody Society, during 2023, 10 antibody therapeutics were granted first approvals in either the US or EU. Thus, increasing development of mAbs and biosimilars is driving the growth of market.
RESTRAINT: Ethical concern related to animal testing
One of the significant ethical concerns related to biologics safety testing, especially in pharmaceutical and biotechnology industries, is the use of animals in testing procedures. Animal studies or in vivo tests are conducted to evaluate the safety profile of biologics, including potential toxicities, immunogenicity, and adverse effects. However, growing ethical concerns about animal welfare and rights have prompted efforts to minimize animal use in testing. Entities engaged in biomedical research must strictly adhere to ethical guidelines, prioritizing the humane care and welfare of animals involved in experiments Ethical problems arise from issues such as insufficient housing, painful procedures, and a lack of enrichment activities, prompting critical reflections on the ethical treatment of animals. Thus, ethical concerns related to animal testing might hamper the growth of market.
OPPORTUNITY: Increasing focus on next generation therapeutics
Next-generation therapeutics encompass innovative approaches and advanced technologies that offer improved efficacy, precision, and safety profiles compared to traditional biopharmaceuticals. Next-generation therapeutics, such as gene therapies, cell-based therapies, RNA therapeutics, immunotherapy, and personalized medicines, are often more complex than conventional small molecule drugs. They may involve genetic manipulation, cell engineering, or targeted delivery systems. This complexity increases the need for thorough safety testing to ensure product quality and patient safety. Thus, increasing focus on next generation therapeutics is driving the growth of biologics safety testing market.
CHALLENGE: Challenges related to biologics complexity and heterogenicity
Biologics encompass a wide range of products such as monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. Each of these has unique structures, mechanisms of action, and potential safety concerns. Biologics often undergo complex post-translational modifications (PTMs) such as glycosylation, phosphorylation, and acetylation. These modifications can impact the safety profile by affecting efficacy, immunogenicity, and stability. Additionally, manufacturing of biologics involves complex processes that can result in batch-to-batch variability. Variations in product quality, purity, and potency can affect safety outcomes. Thus, complexity and heterogeneity of the process make it challenging to manufacture, screen and develop the biologics. Hence, the challenges related to complexities and heterogenicity of biologics are anticipated to hamper the growth of market.
Global Biologics Safety Testing Industry Ecosystem Analysis
The market ecosystem comprises raw material suppliers, biologics safety testing product manufacturers, biologics safety testing service providers, and end users such as pharmaceutical and biotechnology companies, CROs and CDMOs, and academic and research institutes. Biologics safety testing product products manufacturers provide consumables and instruments whereas, biologics safety testing service providers offers wide range of services including endotoxin testing services, mycoplasma testing services, bioburden testing services, virus safety testing services, and sterility testing services.
The residual host cell proteins & DNA detection tests segment dominated biologics safety testing industry in 2023.
Based on test type, the biologics safety testing market is segmented into residual host cell proteins & DNA detection tests, mycoplasma tests, sterility tests, endotoxin tests, virus safety tests, bioburden tests, and other tests. In 2023, residual host cell proteins & dna detection tests segment dominated the market owing to rising demand for biologics and biosimilars. Moreover, rising number of product launches for detection and quantitation of residual host cell proteins and DNA is propelling the segment growth in market.
The pharmaceutical & biotechnology companies segment dominated the biologics safety testing industry in 2023.
Based on end user, the biologics safety testing market is segmented into pharmaceutical & biotechnology companies, CROs and CDMOs, and academic and research institutes. In 2023, pharmaceutical & biotechnology companies segment held the largest market share in the global market owing to rising focus on development of novel biotherapeutics. Additionally, increasing investments and fundings for the advancement of biopharmaceutical industry are promoting the segment growth in market.
North America dominated the biologics safety testing industry in 2023.
To know about the assumptions considered for the study, download the pdf brochure
The global biologics safety testing market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share of market in 2023, followed by Europe and the Asia Pacific. Factors such as significant expenditure on R&D activities, presence of a well-established healthcare market, growing need of advanced therapies are responsible for the largest share of North America region in market.
Key players in the biologics safety testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories (US), BIOMÉRIEUX (France), Maravai LifeSciences (US), WuXi AppTec (China), SGS Société Générale de Surveillance SA. (Switzerland), Sotera Health (Nelson Laboratories, LLC) (US), Samsung Biologics (South Korea), GenScript (US), Agilent Technologies, Inc. (US), Syngene International Limited (India), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Promega Corporation (US), Catalent, Inc (US), ASSOCIATES OF CAPE COD, INC. (US), Pacific BioLabs (US), Clean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc. (US), Frontage Labs (US), Creative Biogene (US), Advaxia Biologics (Italy).
Scope of the Biologics Safety Testing Industry:
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$4.2 billion |
|
Projected Revenue by 2029 |
$7.2 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 11.1% |
|
Market Driver |
Increasing development of mAbs and biosimilars |
|
Market Opportunity |
Increasing focus on next generation therapeutics |
This report categorizes the biologics safety testing market to forecast revenue and analyze trends in each of the following submarkets:
By Product & Service
-
Services
- Mycoplasma Testing Services
- Sterility Testing Services
- Endotoxin Testing Services
- Virus safety Testing Services
- Bioburden Testing Services
- Other Testing Services
- Consumables
- Instrument
By Test Type
- Residual host-cell proteins & DNA detection Tests
- Mycoplasma Tests
- Sterility Tests
- Endotoxin Tests
- Virus Safety Tests
- Bioburden Tests
- Other Biologics Safety Tests
By Application
- Monoclonal Antibodies Development and Manufacturing
- Vaccine Development and Manufacturing
- Cellular & Gene Therapy Products Development and Manufacturing
- Blood & Blood Products Development and Manufacturing
- Other Applications
By End User
- Pharmaceutical & Biotechnology Companies
- CROs and CDMOs
- Academic and Research Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
-
Middle East
-
GCC Countries
- Saudi Arabia (KSA)
- United Arab Emirates (UAE)
- Rest of GCC Countries (RoGCC)
- Rest of Middle East (RoME)
-
GCC Countries
- Africa
Recent Developments of Biologics Safety Testing Industry:
- In January 2024, Chales River Laboratories launched Endosafe Trillium rCR cartridge, a new animal-free testing solution for robust bacterial endotoxin testing.
- In November 2023, Merck KGaA has developed biosafety testing laboratories in Shanghai, China. The facility aims to enable the clients to locally access a broad range of testing services for cell line characterization and lot release from pre-clinical development to commercialization.
- In March 2023, LabCorp collaborated with Forge Biologics for gene therapy development and manufacturing. Under this partnership gene therapy clients will have access to drug development services, manufacturing capabilities, scientific expertise, for adeno-associated virus (AAV) mediated gene therapy programs.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global biologics safety testing market?
The global biologics safety testing market boasts a total revenue value of $7.2 billion by 2029.
What is the estimated growth rate (CAGR) of the global biologics safety testing market?
The global biologics safety testing market has an estimated compound annual growth rate (CAGR) of 11.1% and a revenue size in the region of $4.2 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 52)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 59)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
FIGURE 3 BIOLOGICS SAFETY TESTING INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 5 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2023)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
FIGURE 7 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 8 MARKET: CAGR PROJECTIONS
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 72)
FIGURE 10 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 BIOLOGICS SAFETY TESTING INDUSTRY, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 76)
4.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
FIGURE 15 INCREASING DEVELOPMENT OF MONOCLONAL ANTIBODIES AND BIOSIMILARS TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING INDUSTRY, BY PRODUCT & SERVICE AND COUNTRY (2023)
FIGURE 16 SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
4.3 MARKET SHARE, BY APPLICATION, 2023
FIGURE 17 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.4 MARKET SHARE, BY END USER, 2023
FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT DOMINATED MARKET IN 2023
4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 79)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 BIOLOGICS SAFETY TESTING INDUSTRY: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Development of mAbs and biosimilars
TABLE 3 LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022–2024
FIGURE 21 NUMBER OF ANTIBODY THERAPEUTICS GRANTED A FIRST APPROVAL IN US OR EU, 2012–2023
5.2.1.2 Growing concerns over cell culture contamination
5.2.1.3 Rising investments in biopharmaceutical R&D
FIGURE 22 WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2014–2028
TABLE 4 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)
5.2.1.4 Increasing demand for advanced therapy medicinal products (ATMPs)
TABLE 5 LIST OF APPROVED GENE THERAPIES, 2023–2024
5.2.1.5 Stringent regulatory requirements for biologics safety testing
5.2.2 RESTRAINTS
5.2.2.1 Ethical concerns related to animal testing
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.3.2 Increasing outsourcing of biopharmaceutical activities to CROs
5.2.3.3 Rising focus on next-generation therapeutics
5.2.4 CHALLENGES
5.2.4.1 High cost of biologics
TABLE 6 PRICING OF ADVANCED THERAPIES
5.2.4.2 Challenges related to biologics complexity and heterogenicity
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Polymerase chain reaction (PCR)
TABLE 7 APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING
5.3.1.2 Next-generation sequencing (NGS)
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Lab-on-a-chip (LOC) systems
5.3.2.2 High-content screening (HCS)
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Bioinformatics and computational biology
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 23 MARKET: SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 MARKET: VALUE CHAIN ANALYSIS
5.6 PRICING ANALYSIS
TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
TABLE 9 AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS, BY REGION
5.7 ECOSYSTEM ANALYSIS
FIGURE 25 MARKET: ECOSYSTEM ANALYSIS
5.7.1 RAW MATERIAL VENDORS IN MARKET
TABLE 10 MARKET: ROLE OF RAW MATERIAL VENDORS
5.7.2 PRODUCT VENDORS IN MARKET
TABLE 11 MARKET: ROLE OF PRODUCT VENDORS
5.7.3 SERVICE PROVIDERS IN MARKET
TABLE 12 MARKET: ROLE OF SERVICE PROVIDERS
5.7.4 END USERS IN MARKET
TABLE 13 MARKET: ROLE OF END USERS
5.7.5 REGULATORY BODIES GOVERNING MARKET
TABLE 14 MARKET: ROLE OF REGULATORY BODIES
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 PATENT ANALYSIS
5.9.1 METHODOLOGY
5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
TABLE 15 PATENTS FILED, 2014–2024
5.9.3 INNOVATION AND PATENT APPLICATIONS
FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
5.9.4 TOP APPLICANTS
FIGURE 28 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
TABLE 16 TOP 20 PATENT OWNERS IN MARKET, 2014–2024
TABLE 17 PATENTS IN MARKET, 2024
5.10 KEY CONFERENCES & EVENTS
TABLE 18 MARKET: KEY CONFERENCES & EVENTS, 2024–2025
5.11 REGULATORY LANDSCAPE
5.11.1 INTRODUCTION
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.3 REGULATORY SCENARIO
TABLE 23 MARKET: REGULATORY GUIDELINES
5.12 PORTER’S FIVE FORCES ANALYSIS
FIGURE 29 MARKET: PORTER’S FIVE ANALYSIS
TABLE 24 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICS SAFETY TESTING PRODUCTS
5.13.2 BUYING CRITERIA FOR MARKET
FIGURE 31 KEY BUYING CRITERIA FOR END USERS
TABLE 25 BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES, BY END USER
5.14 INVESTMENT/FUNDING SCENARIO
6 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 117)
6.1 INTRODUCTION
TABLE 26 BIOLOGICS SAFETY TESTING INDUSTRY, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
6.2 SERVICES
TABLE 27 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 28 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.1 MYCOPLASMA TESTING SERVICES
6.2.1.1 Increasing focus on development of biologics and biosimilars to support segmental growth
TABLE 35 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.2 STERILITY TESTING SERVICES
6.2.2.1 Rising focus on development of biologics and biosimilars to drive demand for sterility testing services
TABLE 42 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 43 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.3 ENDOTOXIN TESTING SERVICES
6.2.3.1 Stringent regulatory requirements to drive market
TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.4 VIRUS SAFETY TESTING SERVICES
6.2.4.1 Rising focus on development of advanced therapies to drive growth
TABLE 56 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.5 BIOBURDEN TESTING SERVICES
6.2.5.1 Growing adoption of advanced testing solutions for contamination risk mitigation to propel growth
TABLE 63 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.6 OTHER BIOLOGICS SAFETY TESTING SERVICES
TABLE 70 OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 EUROPE: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 CONSUMABLES
6.3.1 INCREASING DEMAND FOR HIGH-QUALITY ASSAYS AND REAGENTS TO DRIVE MARKET
TABLE 77 BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 LATIN AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 MIDDLE EAST: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 GCC COUNTRIES: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 84 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE (Page No. - 147)
7.1 INTRODUCTION
TABLE 91 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
7.2 RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS
7.2.1 STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO PROPEL MARKET
TABLE 92 RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 EUROPE: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 LATIN AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 MIDDLE EAST: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 GCC COUNTRIES: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MYCOPLASMA TESTS
7.3.1 RISING CONCERNS OF CELL CULTURE CONTAMINATION TO DRIVE MARKET
TABLE 99 MYCOPLASMA TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 STERILITY TESTS
7.4.1 COMPULSORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO SUPPORT SEGMENT GROWTH
TABLE 106 STERILITY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 107 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 MIDDLE EAST: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 ENDOTOXIN TESTS
7.5.1 INCREASING RESEARCH AND DEVELOPMENT FOR PRODUCTION OF BIOLOGICS TO DRIVE MARKET
TABLE 113 ENDOTOXIN TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 VIRUS SAFETY TESTS
7.6.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
TABLE 120 VIRUS SAFETY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.7 BIOBURDEN TESTS
7.7.1 GROWING STRINGENCY OF DRUG SAFETY STANDARDS TO INCREASE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING
TABLE 127 BIOBURDEN TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 128 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 129 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 MIDDLE EAST: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.8 OTHER BIOLOGICS SAFETY TESTS
TABLE 134 OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140 GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
8 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION (Page No. - 170)
8.1 INTRODUCTION
TABLE 141 MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
8.2 MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING
8.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH
TABLE 142 MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 143 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 147 MIDDLE EAST: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 148 GCC: MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 VACCINES DEVELOPMENT AND MANUFACTURING
8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH
TABLE 149 MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 151 EUROPE: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 152 ASIA PACIFIC: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 LATIN AMERICA: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 MIDDLE EAST: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 155 GCC: MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING
8.4.1 INCREASING INVESTMENTS FOR DEVELOPMENT OF CELLULAR & GENE THERAPIES TO DRIVE GROWTH
TABLE 156 MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 157 NORTH AMERICA: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 EUROPE: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 LATIN AMERICA: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161 MIDDLE EAST: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 162 GCC: MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING
8.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROPEL GROWTH
TABLE 163 MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 164 NORTH AMERICA: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 EUROPE: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 166 ASIA PACIFIC: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 167 LATIN AMERICA: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 MIDDLE EAST: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022–2029 (USD MILLION)
TABLE 169 GCC: MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022–2029 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 170 MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 171 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 172 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 MIDDLE EAST: MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 176 GCC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
9 BIOLOGICS SAFETY TESTING MARKET, BY END USER (Page No. - 189)
9.1 INTRODUCTION
TABLE 177 BIOLOGICS SAFETY TESTING INDUSTRY, BY END USER, 2022–2029 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 INCREASING PHARMACEUTICAL R&D SPENDING AND GROWING STRATEGIC ALLIANCES TO DRIVE GROWTH
FIGURE 32 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 (USD BILLION)
TABLE 178 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 179 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183 MIDDLE EAST: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 184 GCC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 CROS & CDMOS
9.3.1 INCREASING FOCUS ON EXPANSION OF CROS AND CDMOS TO PROPEL GROWTH
TABLE 185 MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 186 NORTH AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187 EUROPE: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 188 ASIA PACIFIC: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 LATIN AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 MIDDLE EAST: MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 191 GCC: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO BOOST MARKET GROWTH
TABLE 192 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 193 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 195 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 MIDDLE EAST: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 198 GCC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
10 BIOLOGICS SAFETY TESTING MARKET, BY REGION (Page No. - 201)
10.1 INTRODUCTION
TABLE 199 BIOLOGICS SAFETY TESTING INDUSTRY, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 33 NUMBER OF BIOSIMILARS APPROVED ANNUALLY BY US FDA, 2015 TO 2023
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 34 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
TABLE 200 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 201 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 202 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 203 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 204 NORTH AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 205 NORTH AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.2 US
10.2.2.1 Increasing investments in biotechnology industry to drive market growth
FIGURE 35 TOTAL US NIH BIOTECHNOLOGY FUNDING, FY 2013 TO FY 2024
TABLE 206 US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 207 US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 209 US: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 210 US: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Investments for expanding biomanufacturing capacity to propel market growth
TABLE 211 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 212 CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 214 CANADA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 215 CANADA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3 EUROPE
TABLE 216 EUROPE: INDICATIVE LIST OF APPROVED MONOCLONAL ANTIBODY TREATMENTS
10.3.1 EUROPE: RECESSION IMPACT
TABLE 217 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY/REGION, 2022–2029 (USD MILLION)
TABLE 218 EUROPE: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 219 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 220 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 221 EUROPE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 222 EUROPE: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Expansion initiatives by key market players to support market growth
TABLE 223 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 224 GERMANY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 GERMANY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 226 GERMANY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 227 GERMANY: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.3 UK
10.3.3.1 Emphasis on vaccine manufacturing and biotech R&D to drive market
TABLE 228 UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 229 UK: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 230 UK: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 231 UK: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 232 UK: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising focus on cell & gene therapy R&D to promote market growth
TABLE 233 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 234 FRANCE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 FRANCE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 236 FRANCE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 237 FRANCE: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Rising life sciences R&D and growing biotech industry to boost market
TABLE 238 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 239 ITALY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 ITALY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 241 ITALY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 242 ITALY: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market
TABLE 243 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 244 SPAIN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 SPAIN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 246 SPAIN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 247 SPAIN: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 248 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 249 REST OF EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 250 REST OF EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 251 REST OF EUROPE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 252 REST OF EUROPE: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 36 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
TABLE 253 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 254 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 255 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 257 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 258 ASIA PACIFIC: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China to dominate APAC market
TABLE 259 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 260 CHINA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 CHINA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 262 CHINA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 263 CHINA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Growing government initiatives and expansion of biopharma companies to boost market
TABLE 264 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 265 JAPAN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 266 JAPAN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 267 JAPAN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 268 JAPAN: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Funding for biopharma sector and focus on cell-based therapies to propel market growth
TABLE 269 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 270 INDIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 INDIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 272 INDIA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 273 INDIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Growing focus on advancing bioprocessing sector to drive market
TABLE 274 SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 275 SOUTH KOREA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 SOUTH KOREA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 277 SOUTH KOREA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 278 SOUTH KOREA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.6 AUSTRALIA
10.4.6.1 Rising incidence of chronic diseases and booming life science sector to drive market
TABLE 279 AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 280 AUSTRALIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 AUSTRALIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 282 AUSTRALIA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 283 AUSTRALIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 284 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 285 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 289 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY/REGION, 2022–2029 (USD MILLION)
TABLE 290 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 291 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 293 LATIN AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 294 LATIN AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 Brazil to hold largest share of LATAM market
TABLE 295 BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 296 BRAZIL: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 BRAZIL: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 298 BRAZIL: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 299 BRAZIL: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Increasing government support for biopharmaceutical production to drive market
TABLE 300 MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 301 MEXICO: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 MEXICO: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 303 MEXICO: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 304 MEXICO: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 305 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 306 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 308 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 309 REST OF LATIN AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
TABLE 310 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 311 MIDDLE EAST: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 312 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 314 MIDDLE EAST: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 315 MIDDLE EAST: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2 GCC COUNTRIES
TABLE 316 GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 317 GCC COUNTRIES: MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 318 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 320 GCC COUNTRIES: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 GCC COUNTRIES: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.1 Saudi Arabia
10.6.2.1.1 Increasing healthcare expenditure and rising focus of key players on expansion to support growth
TABLE 322 SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 323 SAUDI ARABIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 324 SAUDI ARABIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 325 SAUDI ARABIA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 326 SAUDI ARABIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.2 United Arab Emirates
10.6.2.2.1 Developing biopharma sector to drive market
TABLE 327 UAE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 328 UAE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 329 UAE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 330 UAE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 331 UAE: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.3 Rest of GCC countries
TABLE 332 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 333 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 335 REST OF GCC COUNTRIES: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 336 REST OF GCC COUNTRIES: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.3 REST OF MIDDLE EAST
TABLE 337 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 338 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 340 REST OF MIDDLE EAST: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 341 REST OF MIDDLE EAST: MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7 AFRICA
10.7.1 RISING PREVALENCE OF CHRONIC DISEASES AND INCREASING GRANTS & FUNDS FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTH
10.7.2 AFRICA: RECESSION IMPACT
TABLE 342 AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 343 AFRICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 AFRICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 345 AFRICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 346 AFRICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 283)
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
TABLE 347 BIOLOGICS SAFETY TESTING MARKET: STRATEGIES ADOPTED
11.3 REVENUE ANALYSIS
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 348 BIOLOGICS SAFETY TESTING INDUSTRY: DEGREE OF COMPETITION
11.5 BRAND/PRODUCT COMPARISON
FIGURE 39 BIOLOGICS SAFETY TESTING INDUSTRY: BRAND/PRODUCT COMPARISON
11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.6.1 STARS
11.6.2 EMERGING LEADERS
11.6.3 PERVASIVE PLAYERS
11.6.4 PARTICIPANTS
FIGURE 40 BIOLOGICS SAFETY TESTING INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.6.5.1 Overall footprint
FIGURE 41 BIOLOGICS SAFETY TESTING INDUSTRY: OVERALL FOOTPRINT
11.6.5.2 Product and service footprint
TABLE 349 BIOLOGICS SAFETY TESTING INDUSTRY: PRODUCT AND SERVICE FOOTPRINT
11.6.5.3 Regional footprint
TABLE 350 BIOLOGICS SAFETY TESTING INDUSTRY: REGIONAL FOOTPRINT
11.6.5.4 Test type footprint
TABLE 351 BIOLOGICS SAFETY TESTING INDUSTRY: TEST TYPE FOOTPRINT
11.6.5.5 Application footprint
TABLE 352 BIOLOGICS SAFETY TESTING INDUSTRY: APPLICATION FOOTPRINT
11.7 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
11.7.1 PROGRESSIVE COMPANIES
11.7.2 RESPONSIVE COMPANIES
11.7.3 DYNAMIC COMPANIES
11.7.4 STARTING BLOCKS
FIGURE 42 BIOLOGICS SAFETY TESTING INDUSTRY: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
11.7.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
TABLE 353 BIOLOGICS SAFETY TESTING INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
TABLE 354 BIOLOGICS SAFETY TESTING INDUSTRY: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
11.8 VALUATION AND FINANCIAL METRICS
FIGURE 43 EV/EBITDA OF KEY VENDORS
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
TABLE 355 BIOLOGICS SAFETY TESTING INDUSTRY: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2024
11.9.2 DEALS
TABLE 356 BIOLOGICS SAFETY TESTING INDUSTRY: DEALS, JANUARY 2021–JANUARY 2024
11.9.3 EXPANSIONS
TABLE 357 BIOLOGICS SAFETY TESTING INDUSTRY: EXPANSIONS, JANUARY 2021–JANUARY 2024
12 COMPANY PROFILES (Page No. - 306)
12.1 INTRODUCTION
12.2 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.2.1 THERMO FISHER SCIENTIFIC INC.
TABLE 358 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 359 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 360 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 361 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
12.2.2 CHARLES RIVER LABORATORIES
TABLE 362 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 363 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 364 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES
TABLE 365 CHARLES RIVER LABORATORIES: DEALS
12.2.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 366 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
FIGURE 47 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 367 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 368 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
TABLE 369 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
12.2.4 F. HOFFMANN-LA ROCHE LTD.
TABLE 370 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 371 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.5 MERCK KGAA
TABLE 372 MERCK KGAA: COMPANY OVERVIEW
FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT
TABLE 373 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 374 MERCK KGAA: EXPANSIONS
12.2.6 SARTORIUS AG
TABLE 375 SARTORIUS AG: COMPANY OVERVIEW
FIGURE 50 SARTORIUS AG: COMPANY SNAPSHOT
TABLE 376 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.7 LONZA
TABLE 377 LONZA: COMPANY OVERVIEW
FIGURE 51 LONZA: COMPANY SNAPSHOT
TABLE 378 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 379 LONZA: PRODUCT LAUNCHES
TABLE 380 LONZA: DEALS
TABLE 381 LONZA: EXPANSIONS
12.2.8 FUJIFILM CORPORATION
TABLE 382 FUJIFILM CORPORATION: COMPANY OVERVIEW
FIGURE 52 FUJIFILM CORPORATION: COMPANY SNAPSHOT
TABLE 383 FUJIFILM CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 384 FUJIFILM CORPORATION: PRODUCT LAUNCHES
TABLE 385 FUJIFILM CORPORATION: DEALS
TABLE 386 FUJIFILM CORPORATION: EXPANSIONS
12.2.9 BIOMÉRIEUX
TABLE 387 BIOMÉRIEUX: COMPANY OVERVIEW
FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT
TABLE 388 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.10 MARAVAI LIFESCIENCES
TABLE 389 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
FIGURE 54 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
TABLE 390 MARAVAI LIFESCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 391 MARAVAI LIFESCIENCES: PRODUCT LAUNCHES
TABLE 392 MARAVAI LIFESCIENCES: DEALS
12.2.11 WUXI APPTEC
TABLE 393 WUXI APPTEC: COMPANY OVERVIEW
FIGURE 55 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 394 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 395 WUXI APPTEC: DEALS
TABLE 396 WUXI APPTEC: EXPANSIONS
12.2.12 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.
TABLE 397 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW
FIGURE 56 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT
TABLE 398 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 399 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: EXPANSIONS
12.2.13 SOTERA HEALTH
TABLE 400 SOTERA HEALTH: COMPANY OVERVIEW
FIGURE 57 SOTERA HEALTH: COMPANY SNAPSHOT
TABLE 401 SOTERA HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 402 SOTERA HEALTH: DEALS
TABLE 403 SOTERA HEALTH: EXPANSIONS
12.2.14 SAMSUNG BIOLOGICS
TABLE 404 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
FIGURE 58 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
TABLE 405 SAMSUNG BIOLOGICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 406 SAMSUNG BIOLOGICS: DEALS
TABLE 407 SAMSUNG BIOLOGICS: EXPANSIONS
12.2.15 GENSCRIPT
TABLE 408 GENSCRIPT: COMPANY OVERVIEW
FIGURE 59 GENSCRIPT: COMPANY SNAPSHOT
TABLE 409 GENSCRIPT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.16 AGILENT TECHNOLOGIES, INC.
TABLE 410 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 60 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 411 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.17 SYNGENE INTERNATIONAL LIMITED
TABLE 412 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
FIGURE 61 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT
TABLE 413 SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 414 SYNGENE INTERNATIONAL LIMITED: DEALS
TABLE 415 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS
12.2.18 EUROFINS SCIENTIFIC
TABLE 416 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 417 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 418 EUROFINS SCIENTIFIC: DEALS
12.2.19 BIO-RAD LABORATORIES, INC.
TABLE 419 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 420 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 421 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES
TABLE 422 BIO-RAD LABORATORIES, INC.: DEALS
12.2.20 QIAGEN
TABLE 423 QIAGEN: COMPANY OVERVIEW
FIGURE 64 QIAGEN: COMPANY SNAPSHOT
TABLE 424 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 425 QIAGEN: PRODUCT LAUNCHES
12.3 OTHER PLAYERS
12.3.1 PROMEGA CORPORATION
TABLE 426 PROMEGA CORPORATION: COMPANY OVERVIEW
12.3.2 CATALENT, INC.
TABLE 427 CATALENT, INC.: COMPANY OVERVIEW
12.3.3 ASSOCIATES OF CAPE COD, INC.
TABLE 428 ASSOCIATES OF CAPE COD, INC.: COMPANY OVERVIEW
12.3.4 CLEAN BIOLOGICS
TABLE 429 CLEAN BIOLOGICS: COMPANY OVERVIEW
12.3.5 PATHOQUEST
TABLE 430 PATHOQUEST: COMPANY OVERVIEW
12.3.6 PACIFIC BIOLABS
TABLE 431 PACIFIC BIOLABS: COMPANY OVERVIEW
12.3.7 ARL BIO PHARMA, INC.
TABLE 432 ARL BIO PHARMA, INC.: COMPANY OVERVIEW
12.3.8 FRONTAGE LABS
TABLE 433 FRONTAGE LABS: COMPANY OVERVIEW
12.3.9 CREATIVE BIOGENE
TABLE 434 CREATIVE BIOGENE: COMPANY OVERVIEW
12.3.10 ADVAXIA BIOLOGICS
TABLE 435 ADVAXIA BIOLOGICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 DISCUSSION GUIDE (Page No. - 396)
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.2 CUSTOMIZATION OPTIONS
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global biologics safety testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biologics safety testing market. The secondary sources used for this study include US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), American Society for Microbiology (ASM), and Biotechnology and Biological Sciences Research Council (BBSRC), Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global biologics safety testing market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechology companies, CROs and CMOs, academic and research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the biologics safety testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the biologics safety testing business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
A biologic drug (biologics) is a product produced from living organisms or contains components of living organisms. Biologics safety testing is carried out by manufacturers to detect contaminants like bacterial toxins, mycoplasma, and viruses. The biologics safety testing market includes instruments, kits, reagents, and services used to identify or quantify contaminants in biologics. Biologics testing is a critical process during development and production, as these large molecules are sensitive to and altered by changes in the manufacturing process, and therefore, quality, safety, and efficacy must be continually monitored in order to meet strict regulatory requirements.
Stakeholders
- Biologics Safety Testing Product Manufacturers, Vendors, and Distributors
- Biologics Safety Testing Service Providers
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Venture Capitalists and Investors
- Government Organizations
- Private Research Firms
- Contract Research Organizations (CROs)
- Contract Development and Manufacturing Organizations (CDMOs)
Report Objectives
- To define, describe, and forecast the global biologics safety testing market based on the product & service, test type, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall biologics safety testing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product and service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the biologics safety testing market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific biologics safety testing market into countries
- A further breakdown of the Rest of Europe biologics safety testing market into countries
- A further breakdown of the Rest of Latin American biologics safety testing market into countries
- A further breakdown of the Rest of Middle East biologics safety testing market into countries
Generating Response ...
Growth opportunities and latent adjacency in Biologics Safety Testing Market
Fantastic piece of content. Thank you for sharing this.